Johnson & Johnson And Tianjin Cancer Hospital To Conduct Joint Drug Research
This article was originally published in PharmAsia News
Executive Summary
Johnson & Johnson and Cancer Hospital of Tianjin Medical University have signed an MOU to jointly develop oncology drugs. Both parties are also discussing the possibility of setting up an oncology R&D collaboration center in Tianjin's Binhai Hi-tech Industrial Park. Cancer Hospital is one of China's largest tumor prevention and treatment bases, housing an advanced tissue bank for tumor specimens. With its strong clinical techniques and resources, the hospital will make an ideal partner for Johnson & Johnson, which seeks to build up a cancer drug R&D base in Asia Pacific. Areas of cooperation will cover animal model studies, local and global clinical trials, technology and knowledge transfer, as well as training for clinicians and researchers. (Click here for more - Chinese language)